[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-337340-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-337340-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","hypofractionated-adjuvant-radiotherapy-in-1-versus-2-weeks-in-high-risk-patients-with-breast-cancer-hypart-a-non-inferiority-open-label-phase-iii-randomised-trial","HYPofractionated Adjuvant RadioTherapy in 1 versus 2 weeks in high-risk patients with breast cancer (HYPART) - a non-inferiority, open-label, phase III randomised trial","","HYPART is a phase III, open-label, non-inferiority trial evaluating hypofractionated adjuvant radiotherapy schedules for high-risk breast cancer patients after surgery. The study compares a 1-week regimen of 26 Gy in 5 fractions with a 2-week regimen of 34 Gy in 10 fractions, targeting locoregional tumor control. Secondary outcomes include early and late radiation toxicities, quality of life, survival, second cancers, and regional or distant metastases, with acute toxicity graded by RTOG and late toxicity assessed using RTOG/EORTC scales. Cosmetic outcomes use Harvard/NSABP/RTOG breast cosmesis grading at baseline and follow-ups, while QoL is measured using EORTC QLQ-30 and QLQ-BR 23.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/hypofractionated-adjuvant-radiotherapy-in-1-versus-2-weeks-in-high-risk-patients-with-breast-cancer-hypart-a-non-inferiority-open-label-phase-iii-randomised-trial/337340/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/hypofractionated-adjuvant-radiotherapy-in-1-versus-2-weeks-in-high-risk-patients-with-breast-cancer-hypart-a-non-inferiority-open-label-phase-iii-randomised-trial/337340.png","ImageObject",300,407,{"name":42,"@type":43},"Jiven","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-07","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the HYPART trial comparing?","Question",{"text":63,"@type":64},"HYPART compares a 1-week hypofractionated adjuvant radiotherapy schedule versus a 2-week schedule in high-risk breast cancer patients after primary surgery.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What radiotherapy doses and fraction schedules are used?",{"text":68,"@type":64},"The 1-week arm delivers 26 Gy in 5 fractions, while the 2-week control arm delivers 34 Gy in 10 fractions.",{"name":70,"@type":61,"acceptedAnswer":71},"What outcomes will be measured during the study?",{"text":72,"@type":64},"Primary outcome is locoregional tumor control. Secondary outcomes include early and late radiation toxicities, quality of life, survival, recurrence patterns, second cancers, and cosmetic assessments.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},337340,1790165339,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":111,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":117,"preview_page_count":33,"preview_urls":144},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","Yadav et al. Trials (2024) 25:21  \n[https://doi.org/10.1186/s13063-023-07851-7](https://doi.org/10.1186/s13063-023-07851-7)  \nTrials  \n STUDY PROTOCOL Open Access  \nHYPofractionated Adjuvant RadioTherapy  \nin 1 versus 2 weeks in high-risk patients with breast cancer (HYPART): a non-inferiority, open-label, phase III randomised trial  \nBudhi Singh Yadav1* , Divya Dahiya2, P. Kannan 1, Shikha Goyal1, Ishita Laroiya2, Santhosh Irrinki2, Ngangom Robert Singh1 and Reena Sharma1  \nAbstract  \nBackground Breast cancer is the most common cancer in women. Radiotherapy is an important part of breast cancer treatment after surgery. Breast cancer radiotherapy is usually delivered in 3–5 weeks. This is a long duration for women with breast cancer to stay away from the family and work. We wanted to reduce this duration so that the wages loss and the logistics can be minimised for these patients. Hypofractionation, i. e. high dose per fraction, is delivered in a smaller number of days. In this study, we will compare a 1-week schedule of hypofractionated adjuvant whole breast/chest wall and/or regional nodal radiotherapy against 2 weeks for locoregional disease control, toxicities, quality of life (QoL), survival and second cancers after primary surgery in patients with breast cancer. Methods Eligible patients with breast cancer after mastectomy or breast conserving surgery (BCS) will be treated with a radiotherapy dose of 26 Gy in 5 fractions over 1 week in the study arm and 34 Gy in 10 fractions over 2 weeks in the control arm. The primary endpoint of this noninferiority study will be locoregional tumour control. Secondary endpoints will be early and late radiation toxicities, quality of life, contralateral primary tumours, regional and distant metastases, survival and second cancers. A total of 1018 patients will be randomised (1:1) to receive 1 week or 2 weeks of radiotherapy. An event-driven analysis will be performed after at least 94 patients have documented locoregional recurrences. Acute radiation toxicity will be assessed and scaled according to the RTOG grading system. Late radiation toxicity will be assessed with the Radiation Therapy Oncology Group and the European Organisation for Research and Treatment of Cancer late radiation morbidity scale. Cosmetic assessment will be done using Harvard/ NSABP/RTOG breast cosmesis grading scale at baseline and 3 and 5 years. QoL will be assessed with EORTC QLQ-30 and EORTC QLQ-BR 23 at baseline and 3 and 5 years.  \nDiscussion Hypofractionation reduces treatment time to half while maintaining breast cosmesis and gives control rates equal to conventional fractionation. This is possible because breast tissue can tolerate high dose per fraction. In this study, we presume that 1-week radiotherapy will be non-inferior to 2 week radiotherapy, i. e. disease control will be similar with both the schedules without additional side effects, and QoL of these patients will be maintained. If we are able to achieve these outcomes, then patients will be able to complete their radiotherapy in less duration. There is not much data on regional nodal irradiation with hypofraction in breast cancer. We have used hypofraction  \n*Correspondence: Budhi Singh Yadav [drbudhi@gmail.com](drbudhi@gmail.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not","cbCaibygvneBYcK2","https://ap.wps.com/l/cbCaibygvneBYcK2","pdf",965661,"English","# Study protocol\n## Background\n## Methods\n## Endpoints and assessments\n## Discussion\n## Trial registration and keywords","[{\"question\":\"What is the HYPART trial comparing?\",\"answer\":\"HYPART compares a 1-week hypofractionated adjuvant radiotherapy schedule versus a 2-week schedule in high-risk breast cancer patients after primary surgery.\"},{\"question\":\"What radiotherapy doses and fraction schedules are used?\",\"answer\":\"The 1-week arm delivers 26 Gy in 5 fractions, while the 2-week control arm delivers 34 Gy in 10 fractions.\"},{\"question\":\"What outcomes will be measured during the study?\",\"answer\":\"Primary outcome is locoregional tumor control. Secondary outcomes include early and late radiation toxicities, quality of life, survival, recurrence patterns, second cancers, and cosmetic assessments.\"}]","HYPofractionated Adjuvant RadioTherapy in 1 versus 2 weeks in high-risk patients with breast cancer (HYPART) - a non-inferiority, open-label, phase III randomised trial | PDF",1790018687,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/09f63460c03d4a6c55148ea5788a1bc5.webp",983,1305,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a52b2c6d7eaa616e7fdd5ac366762bc5.webp",982,1304,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fc8045ca899cbc4a3b278ceb7eaad1b5.webp",981,1303,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a17dda7e191e502a493ed141b046280d.webp",980,1301]